Syndax Pharmaceuticals SNDX AOCI - Available-for-Sale Securities, Net of Tax
AOCI - Available-for-Sale Securities, Net of Tax at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's aoci - available-for-sale securities, net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's AOCI - available-for-sale securities, net of tax?
- Syndax Pharmaceuticals (SNDX) reported AOCI - available-for-sale securities, net of tax of $11K in Q1 2026.
- How has Syndax Pharmaceuticals's AOCI - available-for-sale securities, net of tax changed year-over-year?
- Syndax Pharmaceuticals's AOCI - available-for-sale securities, net of tax decreased by 97.9% year-over-year, from $527K to $11K.
- What is the long-term trend for Syndax Pharmaceuticals's AOCI - available-for-sale securities, net of tax?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's AOCI - available-for-sale securities, net of tax has grown at a 157.4% compound annual growth rate (CAGR), from -$4K to $452K.